Content Type: Article

  • Schulte Submits Comment Letter on SEC’s Proposed Rulemaking on Safeguarding Client Assets

    Schulte Submits Comment Letter on SEC’s Proposed Rulemaking on Safeguarding Client Assets

    ARTICLE / CLIENT ALERT

    Schulte Submits Comment Letter on SEC’s Proposed Rulemaking on Safeguarding Client Assets

    May 23, 2023

    Read time: 2 min

    Key takeaways
    Overview

    Schulte Roth & Zabel recently submitted a comment letter to the U.S. Securities and Exchange Commission on the agency’s proposed safeguarding rule in which SRZ set forth why, in our view, the proposal is unwarranted and risks disruption of important financial markets. The SRZ comment letter focused on a few examples of practical bars to the proposed requirements, including, with respect to the expansion of assets within the rule’s scope, limitations on the privately offered securities exemption, requirements for foreign financial institutions and the impact on digital assets.  

    SRZ is carefully following the development of new rules affecting private investment fund managers and invites continued dialogue on these matters.    

    In depth
    Authors
    More insights

  • IRS Releases Proposed Regulations Addressing Repatriations of Intangible Property

    IRS Releases Proposed Regulations Addressing Repatriations of Intangible Property

    ARTICLE / CLIENT ALERT

    IRS Releases Proposed Regulations Addressing Repatriations of Intangible Property

    May 22, 2023

    Read time: 8 min

    Key takeaways
    Overview

    On May 2, 2023, the Internal Revenue Service (IRS) issued proposed regulations (REG-124064) under Section 367(d) that address repatriations of intangible property to the United States. The proposed regulations terminate the application of Section 367(d)’s annual inclusion if the transferee foreign corporation repatriates the intangible property to a qualified domestic person.

    In depth

    BACKGROUND: SECTION 367(D)

    Section 367(d) generally addresses outbound transfers of intangible property to a foreign corporation. It treats a US transferor that transfers intangible property subject to Section 367(d) as having sold the intangible property in exchange for payments that are contingent on the productivity, use or disposition of the intangible property.

    The US transferor is treated as receiving amounts that reasonably reflect the amounts that would have been received annually in the form of such payments over the useful life of the intangible property or, in the case of a direct or indirect disposition of the intangible property following the transfer, at the time of the disposition. The earnings and profits of the transferee foreign corporation are reduced by the amount of the Section 367(d) inclusion, and the deemed payment is an expense that reduces the transferee foreign corporation’s subpart F income and tested income.

    Section 367(d) regulations provide special “subsequent transfer” rules that apply if the US transferor transfers the stock of the transferee foreign corporation or the transferee foreign corporation transfers the intangible property. These rules depend on whether the transfer is to a US or a foreign person and whether it is to a related or an unrelated person. If the transferee foreign corporation stock or the intangible property is transferred to an unrelated person, the transfer generally is treated as a disposition of the intangible property that triggers a lump sum Section 367(d) inclusion. If the transferee foreign corporation stock is transferred to a related US person, the related US person begins taking into account a proportionate share of the annual Section 367(d) inclusion. If the intangible property is transferred to a related person (either US or foreign), the Section 367(d) inclusions continue, and the recipient of the intangible property is treated as the transferee foreign corporation.

    PROPOSED REGULATIONS: REPATRIATIONS OF 367(D) INTANGIBLE PROPERTY

    Under existing Section 367(d) regulations, a taxpayer who repatriates to the United States intangible property that was previously transferred outbound subject to Section 367(d) (for example, in order to take advantage of the lower tax rate for foreign-derived intangible income) faces the possibility that Section 367(d) could continue to apply. Because the existing regulations do not distinguish between subsequent transfers of intangible property made to a related US or foreign person, there are concerns that in some cases a US transferor may be required to continue recognizing an annual inclusion (potentially without an offsetting deduction) even if the subsequent transfer is to a related US person who will recognize the income derived from the intangible property.

    The proposed regulations provide clarity for taxpayers who repatriate to the United States intangible property that was previously transferred outbound in a Section 367(d) transaction. In particular, the regulations terminate the application of Section 367(d) if the transferee foreign corporation repatriates the intangible property to a qualified domestic person and the domestic person satisfies certain reporting requirements.

    The proposed regulations require the US transferor of the intangible property to recognize gain in certain circumstances. There are different gain recognition rules depending on whether the intangible property is a transferred basis property (i.e., property in which the US transferee’s basis is determined by reference to the transferor foreign corporation’s basis in the property, as would be the case if the intangible property were repatriated in a nonrecognition transaction).

    If the intangible property is a transferred basis property, the transferor foreign corporation recognizes gain (if any) it would recognize under Subchapter C rules. The amount of gain recognized could be zero (for example, if the repatriation transaction is a Section 332 liquidation) or positive (for example, if the repatriation transaction is a Section 351(b) transaction). The US transferee receives the intangible property with a basis equal to the basis the original US transferor of the property had immediately prior to the original outbound transfer (or, if lower, the basis the transferee foreign corporation had in the property), plus the amount of gain recognized on the repatriation.

    If the intangible property is not a transferred basis property (for example, because the intangible property is repatriated in a sale or in a distribution to which Section 311(b) applies), the original US transferor of the intangible property recognizes gain equal to the excess of the fair market value of the intangible property at the time of the repatriation over the original US transferor’s adjusted basis in the property at the time of the original outbound transfer. The US transferee receives the intangible property on a fair market value basis.

    Special rules apply if the intangible property is transferred in two or more related transactions or if there were multiple original US transferors.

    The proposed regulations reduce the transferee foreign corporation’s earnings and profits (but not below zero) by the gain the US transferor recognizes under the gain recognition rule. The US transferor can receive from the transferee foreign corporation an amount equal to the gain recognized without any further tax consequences under an accounts receivable mechanism provided by current regulations.

    Many taxpayers have made prepayments of Section 367(d) amounts. The proposed regulations do not provide specific rules to account for Section 367(d) prepayments in the original outbound intangible property transfer. Accordingly, it appears that the same mechanisms apply without regard to whether there was a prepayment in the original outbound transaction. Failure to account for prepayments creates a possibility that Section 367(d) inclusions taken into account by the original US transferor (including due to the prepayment) may exceed the deductions allowed to the transferee foreign corporation.

    PROPOSED REGULATIONS: OTHER ISSUES

    The proposed regulations address a few other issues besides repatriations of intangible property to the United States. For one, they clarify that the transferee foreign corporation’s earnings and profits reduction must be allocated and apportioned to classes of gross income under the applicable rules under Sections 882, 954 and 960 rather than solely being allocated to subpart F income or tested income.

    The proposed regulations also provide that the subsequent transfer rules, including the repatriation rules described in the proposed regulations, do not apply for purposes of determining the amount of foreign branch income under Section 904. Accordingly, if there were a transfer of intangible property that reallocated income between the foreign branch income category and the general category for purposes of the Section 904 foreign tax credit limitation and that intangible property was further transferred, the subsequent transfer would not cause the reattribution of income for Section 904 purposes to cease.

    In the preamble, the IRS acknowledges that there is uncertainty regarding the treatment of adjusted basis in intangible property subject to Section 367(d). For example, there may be uncertainty regarding the basis of intangible property transferred outbound in a transaction to which Section 367(d) applied and gain is recognized (e.g., due to the presence of boot in the original transaction). The proposed regulations do not address this issue but indicate that it will be addressed in future rulemaking.

    EFFECTIVE DATE

    The rules in the proposed regulations will be effective for transfers of intangible property occurring on or after the date the IRS finalizes the proposed regulations. The proposed regulations do not include a provision allowing taxpayers to rely on them before final regulations are issued, but government officials have indicated that they would consider more flexible approaches in the final regulations.

    CONCLUSION

    The proposed regulations respond to concerns that there could be excessive taxation on repatriations of intangible property to the United States. The proposed regulations terminate the application of Section 367(d) if intangible property is transferred to a qualified domestic person, subject to reporting requirements being satisfied. Overall, the proposed regulations provide welcome clarity to repatriations of intangible property and ensure that taxpayers are not subject to excessive taxation.

    Authors

    Brian H. Jenn

    Partner

    Washington, DC, Chicago

    Elizabeth Chao

    Partner

    Chicago

    More insights

  • New Technology Does Not Alter Enablement Rules

    New Technology Does Not Alter Enablement Rules

    ARTICLE / CLIENT ALERT

    New Technology Does Not Alter Enablement Rules

    May 22, 2023

    Read time: 4 min

    Key takeaways
    Overview

    Exploring the applicability of its enablement law to life sciences, the Supreme Court of the United States issued a unanimous opinion, concluding that patent claims covering a genus of antibodies defined in part by functional limitations were not enabled by the specification as required by 35 U.S.C. § 112. Amgen Inc., et al. v. Sanofi, et al., Case No. 21-757 (S. Ct. May 18, 2023) (Gorsuch, J.).

    Amgen owns a patent covering a class of antibodies that bind to amino acids on the PCSK9 protein and block it from preventing the body from removing cholesterol from the bloodstream. Amgen’s Repatha® product included one such antibody while Sanofi’s Praluent® included another in the class. Amgen sued Sanofi for infringement. After a trial, a US Court of Appeals for the Federal Circuit appeal, a remand and a subsequent trial, the Federal Circuit agreed with Sanofi that Amgen’s patents failed to satisfy the requirement under Section 112(a), which requires that the patent include “a written description of … the manner and process of making [the invention] in such full, clear, concise, and exact terms as to enable any person skilled in the art … to make and use the same.” The Supreme Court granted certiorari to answer the following question:

    Whether enablement is governed by the statutory requirement that the specification teach those skilled in the art to “make and use” the claimed invention, 35 U.S.C. § 112, or whether it must instead enable those skilled in the art “to reach the full scope of claimed embodiments” without undue experimentation—i.e., to cumulatively identify and make all or nearly all embodiments of the invention without substantial “time and effort.”

    After discussing historical enablement cases dealing with inventions like the telegraph and the lightbulb, the Supreme Court reinforced certain principles about enablement law. First, the Court held that the patent specification must enable a person of ordinary skill in the art (POSITA) to make and use the “entire class” when a class is claimed. That said, a specification need not describe every embodiment; rather, the Court explained that it is enough to describe a general quality that would reliably permit a POSITA to make and use the entire claimed scope, “not merely a subset.” To do so, a specification may require a POSITA to perform some adaptation or testing, including reasonable experimentation.

    Applying those principles to the challenged claims, the Supreme Court concluded that, while the 26 antibodies it specifically described were enabled, Amgen’s specification failed to enable a POSITA to make and use all the claimed antibodies. It reasoned that the supposed disclosures were little more than “research assignment[s]” that did not sufficiently guide a skilled artisan.

    As to the precise issue presented on certiorari, the Supreme Court agreed with Amgen that enablement “is not measured against the cumulative time and effort it takes to make every embodiment within a claim.” Yet, the Court found that the key problem was the “trial and error” approach that the specification required.

    Ultimately, the Supreme Court indicated that there was no change in the law, describing the decision as “involv[ing] a new technology,” but with a “legal principle [that] is the same.” It remains to be seen whether the Amgen decision is the end of functional claiming or genus claims or if the case remains an example of well-established principles that will have little impact on the Federal Circuit’s enablement jurisprudence.

    In depth
    Authors
    More insights

  • IRS Issues Reminder that Claims Under Health and Dependent Care FSAs Must Be Substantiated

    IRS Issues Reminder that Claims Under Health and Dependent Care FSAs Must Be Substantiated

    ARTICLE / CLIENT ALERT

    IRS Issues Reminder that Claims Under Health and Dependent Care FSAs Must Be Substantiated

    May 22, 2023

    Read time: 4 min

    Key takeaways
    Overview

    In a recently issued Chief Counsel Advice memorandum, the Internal Revenue Service (IRS) reminded sponsors of health and dependent care flexible spending arrangements (FSAs) of their obligation to properly substantiate claims as a condition of ensuring favorable tax treatment under Section 125 of the Internal Revenue Code (the Code). The IRS’s advice is clear: the substantiation bar is high, and the failure to comply has serious, unwanted consequences for employers. The memorandum includes a useful summary of the applicable law as it applies in six example situations of claims practices.

    In depth

    BACKGROUND

    Code Section 125 allows an employer to establish a cafeteria plan that permits an employee to choose among two or more benefits, consisting of cash (generally, in the form of salary reductions) and qualified benefits, including health coverage or accident insurance. If an employee elects to participate in a health FSA on a pre-tax basis through salary reductions, the value of the coverage by the health FSA and the amounts reimbursed for medical expenses are excludable from gross income up to the allowable limit. Similarly, if an employee elects to participate in a dependent care FSA, the dependent care assistance program benefits are excludable from gross income up to the allowable limit. In each case, however, claims for reimbursement must be properly substantiated.

    Through these examples, the IRS clarifies that a health or dependent care FSA that fails to satisfy the applicable substantiation requirement is not considered a cafeteria plan and, consequently, will not receive favorable tax treatment under Code Section 125. As a result, the full amount of all employee elections between taxable and nontaxable benefits are included in gross income and treated as wages for payroll tax purposes. Substantiation generally requires that all expenses must be supported by information from a third party that is independent of the employee, the employee’s spouse and dependents.

    The IRS provided six examples of how sponsors have substantiated claims in the memorandum:

    Situation 1: The plan only reimburses medical expenses that are substantiated by information from a third party that is independent of the employee and the employee’s spouse and dependents or from an explanation of benefits issued by an insurance company.

    Situation 2: The plan allows for self-certification.

    Situation 3: The plan uses sampling techniques.

    Situation 4: The plan generally requires third-party certification, but it treats certain expenses paid with a debit card as auto-substantiated if the charge is less than a specified dollar amount.

    Situation 5: The plan maintains a list of dentists, doctors, hospitals or other healthcare providers, the charges from which are treated as auto-substantiated.

    Situation 6: A dependent care assistance plan allows employees to submit a form in advance of receiving the dependent care, attesting to the amount of dependent care expenses they will incur in the upcoming year and to thereafter notify the plan sponsor only if the anticipated amount of expenses change.

    According to the memorandum, only Situation 1 complies with the applicable substantiation requirements of Code Section 125. The plans in Situations 2 through 6 fail to do so. Thus, all employee election amounts in Situations 2 through 6 are treated as taxable for both income and payroll tax purposes.

    The IRS’s holdings are all based on the 2007 proposed regulations, which do not have the force of law. Nevertheless, plan sponsors and their advisors have long looked to these proposed rules for guidance. The memorandum itself also provides that it may not be used or cited as precedent. Therefore, employers that sponsor health and dependent care FSAs should review their vendor service agreements and plan administration to ensure the agreements and plan operations comply with the requirements of Code Section 125.

    For any questions, please contact your regular McDermott lawyer or one of the authors.

    Authors

    Jacob M. Mattinson

    Partner

    Chicago

    Sarah G. Raaii

    Partner

    Chicago

    More insights

  • Remote Monitoring Services Under Review: Update on Potential Medicare Coverage Policies

    Remote Monitoring Services Under Review: Update on Potential Medicare Coverage Policies

    ARTICLE / CLIENT ALERT

    Remote Monitoring Services Under Review: Update on Potential Medicare Coverage Policies

    May 22, 2023

    Read time: 11 min

    Key takeaways
    Overview

    MAY 2023 UPDATE

    On May 19, 2023, Novitas Solutions and First Coast Options sent an email to certain interested parties, with whom they had engaged following the multijurisdictional contractor advisory committee (CAC) meeting, explaining that they have decided to not pursue at this time a local coverage determination for remote physiological monitoring (RPM) and remote therapeutic monitoring (RTM).

    What does this communication mean for RPM/RTM service providers?

    In the short term, the status quo remains (i.e., there is no proposed local coverage determination) for Novitas and First Coast. This communication is specific to Novitas and First Coast, and does not prevent the other Medicare Administrative Contractors (MACs) from developing local coverage determinations for their jurisdictions. Novitas and First Coast may change their mind at any time and decide to draft a proposed local coverage determination for RPM and/or RTM services. Further, if any of the MACs decide to issue a draft LCD, they are not obligated to hold another CAC meeting or to notify stakeholders in advance.

    Accordingly, healthcare providers and digital health companies should continue their focus on compiling the evidence to support the clinical utility of their services. This action (or inaction) by Novitas and First Coast should not be misinterpreted as a justification for easing off evidence generation and collection.

    In depth

    SUMMARY

    A recent multijurisdictional CAC meeting held by six of the seven MACs gave stakeholders an initial opportunity to provide feedback on the strength of clinical evidence to support Medicare coverage for RPM and RTM services for non-implantable medical devices. We previewed how this meeting may influence the development of Medicare local coverage determinations in a recent article.

    Twenty-four subject matter experts (SMEs), both physicians and other stakeholders, including digital health company medical leaders and clinicians with extensive experience with remote monitoring programs participated in the CAC meeting. The questions posed during the CAC meeting included requests for examples of SME experience with remote monitoring technologies and opinions on the amount of high-quality evidence to support their use for various diagnoses and conditions.

    Despite certain questions posed during the CAC meeting that demonstrated a skepticism for remote monitoring services outside certain use cases, the SMEs voiced overwhelming support for continued coverage of remote monitoring services and several SMEs expressed concern about the potential proposal of one or more local coverage determinations (each, a LCD). Several participants noted that literature and data not referenced in the meeting materials, together with pending research studies, could provide support for continued coverage of remote monitoring services for a variety of clinical uses.

    BACKGROUND

    Remote Monitoring Background

    In recent years, the Centers for Medicare & Medicaid Services expanded payment for remote monitoring services, which generally use digital technologies (medical devices, together with software) to collect medical and other forms of health data from patients in one location and electronically transmit the information to the patient’s healthcare provider in a different location for assessment and care management. The data collected is electronically transmitted to health professionals for review and can be used in patient management. In some cases, the technologies can either trigger direct patient engagement or facilitate that communication.

    RPM services involve monitoring physiological conditions (e.g., weight, blood pressure, blood sugar) through medical devices, which transmit data obtained from patients automatically to healthcare providers for assessment and recommendations. In contrast to RPM services, RTM services involve the use of medical devices to monitor a patient’s health or response to treatment using non-physiological data. RTM can be used to monitor medication adherence, response to therapy, musculoskeletal activity and respiratory activity. Unlike RPM, devices for RTM are not limited to transmitting data automatically obtained from patients but can also transmit data self-reported by patients.

    Medicare Coverage Policies and Role of CACs

    In determining whether to develop an LCD for particular services, MACs may, but are not required to, hold a CAC meeting as an opportunity for healthcare providers to provide feedback (i.e., evidence) that the MAC contract medical directors can consider when contemplating the potential development of future coverage policies. CACs provide a forum for communications between the MACs and the healthcare industry more broadly. CACs are advisory only, however, and the final decision on whether to proceed with a draft LCD remains at the discretion of the MAC. If a MAC decides to draft an LCD, it will be published on the Medicare Coverage Database and on the MAC’s websites. After the publication, the public will have at least 45 days to provide written comments, as well as an opportunity to deliver comments verbally during an “open meeting” before the LCD is finalized. A MAC will then consider the submitted evidence and comments before taking final action on the draft LCD. This final action must be taken within 365 days of the draft LCD being published, and it can be finalized, revised or withdrawn. MACs are required to respond to submitted comments in a comment/response document published alongside any final LCD. Once a MAC publishes a final LCD, there must be a minimum 45-day notice period prior to the policy becoming effective.

    IN DEPTH

    Key Takeaways

    The recent CAC meeting focused on the clinical use of remote monitoring technologies and the quantity and extent of clinical literature supporting the use of RPM and RTM across specialties. The stated purpose of the CAC meeting was to examine the quality and strength of the clinical evidence supporting remote monitoring technologies, discuss the relevance of the evidence to the Medicare population, and obtain opinions from a variety of clinical backgrounds. The CAC meeting involved the MAC medical directors and certain SMEs on remote monitoring services.

    The SMEs overwhelmingly supported the use of remote monitoring technologies and services across a wide variety of specialties. The SMEs advocated for continued Medicare coverage of this type of treatment and highlighted a variety of success stories. The SMEs were asked questions on their clinical use, and also on the evidence to support use, as detailed below.

    Clinical Use of Remote Monitoring

    The SMEs provided background on their clinical practice and reasoning for using RPM or RTM technologies. SMEs that utilize remote monitoring technologies were asked to discuss how they identify potential patients, how long patients are monitored, and what patient diagnoses are suitable for RPM or RTM services. The SMEs represented specialties including cardiology, physical therapy, internal medicine, podiatry, pediatrics, geriatrics, urology, anesthesiology, interventional pain management and orthopedics.

    The majority (if not all) of the SMEs had extensive experience with either RPM or RTM, with many clinicians leveraging both technologies. The SMEs discussed at length the benefits of having data regularly collected by remote technologies and the value of being able to engage patients both sooner and more regularly when compared to in-person care. SMEs highlighted more regular contact with patients and access to data on patients’ clinical status in particular as beneficial with respect to chronic conditions and patients who may receive less regular in-person care because of limited access to regular care. As one expert from Mount Sinai remarked, having access to data from high-risk patients allows for higher intensity care in a cost-effective manner.

    Another area where there was broad agreement related to the need to accommodate variation in the length of monitoring for patients. The SMEs stated that the duration of remote monitoring was dependent on the patient’s condition and the treating practitioner’s particular evaluation. Ranges between four weeks and up to six months were offered, depending on the patient and the ongoing utility of remote monitoring, although other participants noted that remote monitoring can be of use for longer periods of time for patients with chronic conditions or for patients receiving RTM as part of a physical therapy plan of care.

    Remote Physiologic Monitoring Use Cases

    RPM was discussed across the majority of specialties, with specific discussions on the advantages of filling in data points for patients that are not seen often. The most frequently mentioned clinical uses of RPM services included the following:

    • Patients diagnosed with the below conditions where consistent monitoring can aid in medical decision making:
      • Diabetes
      • Neuropathy
      • Musculoskeletal traumatic arthropathy
      • Vascular disease
      • Hypertension
      • Chronic heart failure
    • Patients with more than one hospital stay in one year
    • Patients who utilize healthcare resources or visit emergency departments frequently
    • Patients who have had an escalation of their condition in the last 24 months
    • Patients who are geographically disadvantaged to seek in-person care
    • Patients with obstructive sleep apnea who use CPAP machines
    • Patients with chronic obstructive pulmonary disease (COPD) exacerbation
    • Chronic heart failure patients, specifically in relation to reducing hospital readmissions.

    Remote Therapeutic Monitoring Use Cases

    Similarly, RTM was widely discussed. The clinical use cases noted to have particular advantages included medication adherence and physical therapy monitoring. The clinical use cases for RTM included the following:

    • Ensuring patients are adherent with therapy plans of care and are following therapist directions with respect to physical therapy exercises
    • Medication adherence monitoring, specifically for identifying and monitoring the development of substance use disorders for chronic pain patients
    • Providing ongoing monitoring to patients recovering from total knee replacements and to reduce the number of in-person physical therapy visits
    • Monitoring the use of inhalers for patients with asthma and COPD.

    Evidence-Supported Outcomes

    The SMEs were asked to provide opinions on the amount and quality of literature supporting the use of RPM and RTM. The SMEs felt existing literature supported the use of RPM and RTM over established standards of care in several areas, including elevating patient engagement, improving patient care and reducing overall healthcare utilization. Several SMEs highlighted ongoing studies in the following areas:

    • The value of RPM for hypertension and hyperlipidemia patients
    • The correlation between the use of remote monitoring and improvements in health equity
    • Use of remote monitoring in orthopedics and musculoskeletal treatment
    • Improvements over the standard of care for treatment of patients with diabetic ulcers.

    During the meeting, participants were asked whether there is high-quality evidence to support the use of remote monitoring for patient diagnoses other than chronic heart failure, hypertension, COPD, hemoglobin A1c (blood glucose monitoring for diabetes), back/knee pain and musculoskeletal conditions. Based on this question, the CAC may believe that the clinical evidence is stronger for these conditions, and views the evidence as less robust with respect to other conditions or use cases. Due to the number of SMEs participating in the meeting (and the extensive responses to certain questions provided by the SMEs), the MAC medical directors did not weigh in or provide additional insight as to how they are viewing the clinical support for various conditions or use cases.

    Several individuals raised concern about the MACs implementing coverage policies before currently pending studies have been published, stating that these programs need time to finish and develop. Some commenters suggested that the timing of the availability of these codes—either shortly before (in the case of RPM) or shortly after (in the case of RTM) the start of the public health emergency—hindered efforts to collect data effectively on many of the remote monitoring services. Other commenters raised concern about implementing restrictive coverage policies before RPM services in particular have a chance to demonstrate value through published studies for use cases other than the conditions noted above. There were specific concerns over the implementation of LCDs by MACs that negatively impact coverage and payment for remote monitoring services more broadly, particularly in the Medicaid population.

    Practical Impact

    As discussed above, the CAC meeting is one of the first steps before an LCD may be proposed. If a MAC (or MACs) do propose an LCD, potential coverage limitations may relate to the particular conditions for which remote monitoring services are viewed as reasonable and necessary and the duration of remote monitoring that may be provided. Although the CAC meeting did not include meaningful discussion on the types of devices furnished to Medicare beneficiaries in connection with remote monitoring services, an eventual LCD could also potentially implement limitations on the types of devices for which remote monitoring services are considered reasonable and necessary.

    Digital health companies that furnish these services (or help providers furnish these services) and have access to persuasive literature or have concerns about potential limitations in an eventual LCD should strongly consider submitting feedback and literature for consideration. The most persuasive literature or information will include evidence on what specific medical devices are used and which patient diagnoses are supported by clinical data, and how the use of RPM or RTM services impacts patient management and improves patient outcomes (for example, lowers the likelihood of side effects post-surgery, reduces the incidence of chronic condition exacerbation, or reduces recurrent hospitalizations or office visits). Healthcare providers with evidence to support the clinical utility of RPM and RTM services should similarly focus on compiling such evidence. This evidence will be crucial for establishing that the use of particular devices for certain diagnoses provides clinical benefit to the patient.

    CAC participants are permitted to submit additional comments and/or literature to medicalaffairs@guidewellsource.com no later than March 10, 2023. The audio and transcript of the recording will be posted publicly on MAC websites within four weeks.

    Authors

    Caroline Reignley

    Partner

    Washington, DC

    Michael W. Ryan

    Partner

    Washington, DC

    Marshall E. Jackson , Jr.

    Partner

    Washington, DC

    More insights

  • A Brief Overview of California’s Plastic Pollution Prevention and Packaging Producer Responsibility Act SB 54

    A Brief Overview of California’s Plastic Pollution Prevention and Packaging Producer Responsibility Act SB 54

    ARTICLE / CLIENT ALERT

    A Brief Overview of California’s Plastic Pollution Prevention and Packaging Producer Responsibility Act SB 54

    May 22, 2023

    Read time: 5 min

    Key takeaways
    Overview

    The Plastic Pollution Prevention and Packaging Producer Responsibility Act (SB 54) shifts plastic pollution responsibilities in California from consumers to producers. The law’s objective is to reduce plastic material in the state incrementally by 2032. Although CalRecycle is in the process of developing the specific requirements, it is important that manufacturers, brand owners and other entities doing business in California are aware of this new law. It is likely to have far reaching impacts on many consumer products companies by assessing user fees and new recycling requirements on the types of plastic packaging sold in California.

    In depth

    Materials Covered by the Law

    SB 54 applies to single-use packaging that is routinely recycled, disposed of or discarded after its contents have been used or unpackaged. This includes items that are typically not refilled or otherwise reused by the producer. It also includes plastic single-use food service ware.

    Goals of SB 54

    In order to comply with the law’s requirements, plastic producers should meet the following objectives:

    1. Reduce the overall amount of plastic material (including products packaged in such material) in California by 10% by 2027, 20% by 2030 and 25% by 2032. Methods of reduction may include shifting current materials to reusable/refillable alternatives or eliminating unnecessary packaging or components of packaging.
    2. Ensure that all material covered by SB 54 (broader than just plastic) in the state is recyclable or compostable by 2032.
    3. Achieve the following recycling rates for all plastic material in the state: a. No less than 30% by January 1, 2028 b. No less than 40% by January 1, 2030 c. No less than 65% by January 1, 2032.

      i. In 2021, only 5% of postconsumer plastic waste in the United States was recycled.

    These objectives require “producers” (explained below) to move away from their current plastic packaging and single-use plastic.

    Who Is Affected?

    The law defines producers broadly, implicating brand owners and those participating in the manufacturing, advertising, distribution or sale of a plastic-containing consumer product in California. There are specific exemptions for small businesses; human and animal medical products (e.g., drugs, pharmaceuticals and medical devices); infant formulas; medical foods; prescription supplements; FIFRA-regulated products; beverage containers; packaging used to contain and ship dangerous or hazardous goods; and goods packaged for long-term storage (i.e., five years or more). Ultimately, the responsible producer is a fact-specific inquiry that evaluates the various parties involved in the production and promotion of a relevant product.

    What’s a PRO?

    The law requires producers to join a producer responsibility organization (PRO) by January 1, 2024. A PRO is a nonprofit entity responsible for ensuring its members comply with SB 54. PROs must submit a plan to CalRecycle, outlining the steps their members will take to achieve the plastic reduction targets set forth in the law. CalRecycle is responsible for reviewing and approving these plans, which are reassessed every five years. Producers may comply individually without joining a PRO, but only if they can demonstrate a recycling rate of at least 65% in the three years prior to January 1, 2027, and a recycling rate at or above 70% annually thereafter.

    PRO Plan and Budget Process

    PROs must submit a proposed plan and budget to CalRecycle’s advisory board for review and comment. The advisory board has 60 days to provide written feedback, along with any public comments. A PRO may then incorporate these comments into its plan. The plan should include the following components (among others):

    • Actions and investments taken by the PRO to meet the law’s requirements
    • A source reduction plan (including a timeline and actions to discontinue use)
    • Technologies and means used to achieve recycling requirements
    • Objective and measurable criteria regarding the economics of collecting, processing, recycling, composting, sorting and segregating materials—leveraging existing collection programs when possible
    • Use of solid waste collection programs and facilities for curbside collection and processing
    • Maintenance of existing franchise agreements
    • How material will be collected, processed, managed, recycled, remanufactured or composted consistent with the goals outlined in the law
    • Arrangements with processors or recyclers, including investments made to cover the cost of materials being processed or recycled
    • Arrangements to establish and fund reuse or refill infrastructure, facility retrofits or other necessary infrastructure to comply with the goals outlined in the law
    • How postconsumer recycled (PCR) content will be incorporated into the covered materials (including the amounts of PCR content)
    • How the plan will be implemented to achieve the reduction targets over time
    • Plans for education, outreach, etc.

    The plan should include a fee structure and schedule that the PRO will use to collect fees from producers that participate in the approved plan. The PRO is required to submit an annual report and budget that describes how the PRO and each of its participating producers are implementing the approved plan and complying with the requirements of the law.

    Penalties

    Failure to comply with SB 54 could result in civil penalties up to $50,000 per day, per violation. Accruals for such penalties begin 30 days after notification of the violation.

    Conclusion

    Consumer product companies should continue to monitor the developments associated with SB 54. Notably, CalRecycle will be hosting an informal public workshop about SB 54 on May 31, 2023. Interested parties may attend in person or over webcast.

    Authors
    More insights

  • Digital Health Forum 2023

    Digital Health Forum 2023

    ARTICLE

    Digital Health Forum 2023

    May 18, 2023

    Read time: 2 min

    Key takeaways
    Overview

    Digital Health Forum 2023 brought together senior leaders transforming digital health for important discussions on the business, operational and policy issues impacting the future of healthcare. Check out the key takeaways below for insights from the conference.

    In depth
    Authors
    More insights

  • Digital Health Laws & Regulations 2023: France

    Digital Health Laws & Regulations 2023: France

    ARTICLE

    Digital Health Laws & Regulations 2023: France

    May 2023

    Read time: 2 min

    Key takeaways
    Overview

    ICLG’s unmissable, comprehensive guide to the field of Digital Health contains everything you need to know about digital health and healthcare, including regulatory issues, data use, data sharing, health technology, health IP, commercial agreements and AI & machine learning.

    Our French healthcare team contributed the France chapter of the guide, which covers everything businesses should know to place themselves strategically within the sector, and look ahead to burgeoning opportunities.

    Read the full chapter, “Digital Health Laws and Regulations France 2025.”

    In depth
    Authors

    Caroline Noyrez

    Associate

    Paris

    Alice Villagrasa

    Associate

    Paris

    More insights

  • IRS Announces 2024 Limits for Health Savings Accounts, High-Deductible Health Plans and Excepted Benefit HRAs

    IRS Announces 2024 Limits for Health Savings Accounts, High-Deductible Health Plans and Excepted Benefit HRAs

    ARTICLE / CLIENT ALERT

    IRS Announces 2024 Limits for Health Savings Accounts, High-Deductible Health Plans and Excepted Benefit HRAs

    May 17, 2023

    Read time: 2 min

    Key takeaways
    Overview

    Recently, the Internal Revenue Service (IRS) announced (See Revenue Procedure 2023-23) cost-of-living adjustments to the applicable dollar limits for health savings accounts (HSAs), high-deductible health plans (HDHPs) and excepted benefit health reimbursement arrangements (HRAs) for 2024. All of the dollar limits currently in effect for 2023 will change for 2024, with the exception of one limit. The HSA catch-up contribution for individuals ages 55 and older will not change as it is not subject to cost-of-living adjustments.

    The table below compares the applicable dollar limits for HSAs, HDHPs and excepted benefit HRAs for 2023 and 2024.

    HEALTH AND WELFARE PLAN LIMITS 2023 Δ 2024
    HDHP – Maximum annual out-of-pocket limit (excluding premiums)
    Self-only coverage $7,500 ↑ $8,050
    Family coverage $15,000 ↑ $16,100
    HDHP – Minimum annual deductible
    Self-only coverage $1,500 ↑ $1,600
    Family coverage $3,000 ↑ $3,200
    HSA – Annual contribution limit
    Self-only coverage $3,850 ↑ $4,150
    Family coverage $7,750 ↑ $8,300
    Catch-up contributions (ages 55 and older) $1,000 = $1,000
    Excepted Benefit HRA
    Annual contribution limit $1,950 ↑ $2,100

    NEXT STEPS

    Plan sponsors should update payroll and plan administration systems for the 2024 cost-of-living adjustments and incorporate the new limits in relevant participant communications, such as open enrollment and communication materials, plan documents and summary plan descriptions.

    For further information about applying the new HSA, HDHP and excepted benefit HRA plan limits for 2024, please contact your regular McDermott lawyer or one of the authors below.

    In depth
    Authors

    Jacob M. Mattinson

    Partner

    Chicago

    Sarah G. Raaii

    Partner

    Chicago

    More insights

  • Florida Passes Law Restricting Foreign Ownership of Real Estate

    Florida Passes Law Restricting Foreign Ownership of Real Estate

    ARTICLE / CLIENT ALERT

    Florida Passes Law Restricting Foreign Ownership of Real Estate

    May 16, 2023

    Read time: 8 min

    Key takeaways
    Overview

    The Florida Legislature recently passed Senate Bill 264 (SB 264), which Governor Ron DeSantis signed into law on May 8, 2023. SB 264 notably presents several new restrictions on persons or entities from certain foreign countries of concern, which are defined as the People’s Republic of China, the Russian Federation, the Islamic Republic of Iran, the Democratic People’s Republic of Korea, the Republic of Cuba, the Venezuelan regime of Nicolás Maduro or the Syrian Arab Republic.

    SB 264 particularly (1) prohibits governmental entities in Florida from contracting with any foreign country of concern, (2) prohibits governmental entities in Florida from entering into any contract or agreement granting economic incentives to a foreign country of concern, (3) prohibits the ownership of agricultural land and certain asset classes (such as real property located near a military installation or critical infrastructure) by foreign principals of any foreign country of concern, and (4) largely restricts most ownership by foreign principals from the People’s Republic of China.

    There are only minimal carve-outs to these restrictions; as such, the implications of SB 264 will be widely felt by the Florida real estate industry.

    In depth

    RESTRICTIONS ON OWNERSHIP OF AGRICULTURAL LAND

    SB 264 creates §§ 692.202-204. Newly enacted § 692.202 provides that a foreign principal may not directly or indirectly own, have a controlling interest in, or acquire agricultural land or any interest therein other than a de minimus indirect interest. “Agricultural land” is defined as land classified as agricultural under Florida Statute § 193.461. Florida Statute § 193.461(b) states that “[s]ubject to the restrictions specified in this section, only lands that are used primarily for bona fide agricultural purposes shall be classified agricultural. The term ‘bona fide agricultural purposes’ means good faith commercial agricultural use of the land.”

    A foreign principal has a de minimus indirect interest if any ownership is the result of the foreign principal’s ownership of registered equities in a publicly traded company owning the land and if the foreign principal’s ownership interest in the company is either (a) less than 5% of any class of registered equities or less than 5% in the aggregate in multiple classes of registered equities; or (b) a noncontrolling interest in an entity controlled by a company that is both registered with the US Securities and Exchange Commission as an investment adviser under the Investment Advisers Act of 1940, as amended, and is not a foreign entity.

    Section 692.202(1) carves out agricultural land owned before July 1, 2023, but creates a registration requirement for foreign principals who continue to own agricultural land after such date. Failure to timely register will subject the foreign principal to a $1,000 civil penalty for each day that the registration is late and could result in the Florida Department of Agriculture and Consumer Services (Department of Agriculture) placing a lien against the unregistered agricultural land for the unpaid balance of any late penalties. Section 692.202(5)(a) also mandates that, at the time of purchase, a buyer of agricultural land must provide an affidavit under penalty of perjury attesting that the buyer is not a foreign principal and is in compliance with § 692.202 requirements. It is worth noting that failure to comply with this statutory requirement does not affect the title or insurability of the land.

    Additionally, § 692.202(6) contains numerous consequences for ownership of agricultural land in violation of the section, including (1) forfeiture to the state, (2) a civil action by the Department of Agriculture for forfeiture, (3) the recording of a lis pendens, (4) a final judgment of forfeiture vesting title to the land in the state, (5) sale of the land previously subject to forfeiture, and (6) an ex parte order of seizure in cases of clear and present danger to the state. Moreover, knowingly violating the statute is a misdemeanor of the second degree.

    RESTRICTIONS ON OWNERSHIP OF REAL PROPERTY NEAR MILITARY INSTALLATIONS AND CRITICAL INFRASTRUCTURE FACILITIES

    SB 264 also creates § 692.203, which prohibits the purchase of real property around military installations and critical infrastructure facilities by foreign principals. Under this provision, a foreign principal may not directly or indirectly own, have a controlling interest in, or acquire by purchase, grant, devise, or descent any interest (except a de minimus indirect interest) in real property on or within 10 miles of any military installation or critical infrastructure facility in Florida.

    Despite the restrictions in § 692.203(1), SB 264 also includes an exception—similar to that in § 692.202(2)—permitting a foreign principal to continue holding an interest in such property if they directly or indirectly owned the property before July 1, 2023. Likewise, § 692.203 includes registration requirements (albeit with the Florida Department of Economic Opportunity, not the Department of Agriculture) and imposes civil and criminal penalties similar to those in § 692.202.

    RESTRICTION ON OWNERSHIP OF REAL PROPERTY BY THE PEOPLE’S REPUBLIC OF CHINA

    SB 264 § 692.204 prohibits the purchase or acquisition of real property by the People’s Republic of China and certain other enumerated persons and entities as set forth below. Specifically, the following persons or entities may not directly or indirectly own, have a controlling interest in, or acquire by purchase, grant, devise, or descent any interest (except a de minimus indirect interest) in real property in Florida:

    1. The People’s Republic of China, the Chinese Communist Party or any official or member of either group.
    2. Any other political party or member of a political party or a subdivision of a political party in the People’s Republic of China.
    3. A partnership, association, corporation, organization or any other combination of persons organized under the laws of or having its principal place of business in the People’s Republic of China or a subsidiary of such entity.
    4. Any person who is domiciled in the People’s Republic of China and is not a citizen or lawful permanent resident of the United States.
    5. Any person, entity or collection of persons or entities described in subparagraphs 1 through 4 as having a controlling interest in a partnership, association, corporation, organization, trust or any other legal entity or subsidiary formed for the purpose of owning real property in Florida.

    A “de minimus indirect interest” is defined similarly to the above SB 264 statutory provisions. Unlike the other newly created statutes in SB 264, however, it seems that § 692.204(1)(a)5. expands SB 264’s reach by including applicability to a “collection of persons or entities . . . having a controlling interest,” as described in § 692.204(1)(a). This language implies that the de minimus interests collectively could not have a controlling interest in any such legal entity that owns real property in Florida.

    Notwithstanding the above property ownership restrictions, SB 264 § 692.204(2) permits a natural person described in (1)(a) to purchase one residential real property that is up to two acres in size if (1) the parcel is not on or within five miles of any military installation in this state; (2) the person has a current verified US visa authorizing them to be legally present within this state; and (3) the purchase is in the name of the person who holds the visa or official documentation.

    Additionally, as with § 692.202(3)(a) and § 692.203(3)(a), § 692.204 creates a registration requirement with the Department of Economic Opportunity. Likewise, § 692.204 mandates that the buyer of real property submit an affidavit under penalty of perjury attesting to the fact that the buyer is not a person or entity listed in (1)(a) and is in compliance with the requirements of this section. Failure to comply with this statutory requirement does not affect the title or insurability of the land. Section 692.204 also imposes civil and criminal penalties for violations of this provision, although the criminal penalties are different from those mentioned above. § 692.204(8) particularly states that a violation of this section constitutes a felony of the third degree while § 692.204(9) states that a person who knowingly sells real property or any interest therein in violation of this section commits a misdemeanor of the first degree.

    McDERMOTT INSIGHT

    SB 264 presents many challenges for foreign nationals and entities who wish to own (or already own) real property in Florida. McDermott Will & Emery has already begun to advise clients on navigating the complexities of SB 264 and encourages anyone who believes they may be impacted by the bill to immediately review their organizational structure and ownership, as well as the location of every real estate project in Florida. For assistance with this review, please contact the authors of this article.

    Authors

    Elena Otero

    Partner

    Miami

    Kelly Shami

    Partner

    Miami

    More insights